BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol. 2009;26:32-37. [PMID: 18498064 DOI: 10.1007/s12032-008-9077-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:53-58. [PMID: 23378775 DOI: 10.2147/ott.s41383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
2 Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer 2012;3:7-13. [PMID: 22211140 DOI: 10.7150/jca.3.7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
3 Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. Cancer Treat Rev. 2014;40:701-715. [PMID: 24731471 DOI: 10.1016/j.ctrv.2014.02.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
4 Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Targ Oncol 2013;8:83-96. [DOI: 10.1007/s11523-013-0281-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
5 Villanueva A, Stockert JC, Cañete M, Acedo P. A new protocol in photodynamic therapy: enhanced tumour cell death by combining two different photosensitizers. Photochem Photobiol Sci 2010;9:295-7. [PMID: 20221454 DOI: 10.1039/b9pp00153k] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
6 McCann GA, Smith B, Backes FJ, Rath K, Chacko S, Salani R, Eisenhauer E, Fowler JM, Cohn DE, O'Malley DM. Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen? Gynecol Oncol 2012;127:362-6. [PMID: 22885866 DOI: 10.1016/j.ygyno.2012.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
7 Jiang Z, Wang X, Tan X, Fan Z. Effect of Age on Survival Outcome in Operated and Non-Operated Patients with Colon Cancer: A Population-Based Study. PLoS One 2016;11:e0147383. [PMID: 26789841 DOI: 10.1371/journal.pone.0147383] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
8 Yang Q, Yin C, Liao F, Huang Y, He W, Jiang C, Guo G, Zhang B, Xia L. Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer. Onco Targets Ther 2015;8:2407-13. [PMID: 26366095 DOI: 10.2147/OTT.S88679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
9 Seemann H, Meran JG. Sinnhaftigkeit und Dauer von palliativer Chemotherapie in Bezug auf die Lebensqualität betroffener Patienten. Wien Med Wochenschr 2010;160:64-9. [DOI: 10.1007/s10354-010-0752-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Weinreich J, Struller F, Sautkin I, Giuashvili S, Reymond M, Königsrainer A, Schott TC. Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro. Invest New Drugs 2019;37:415-23. [PMID: 30019100 DOI: 10.1007/s10637-018-0641-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. Jpn J Clin Oncol 2011;41:490-7. [PMID: 21303790 DOI: 10.1093/jjco/hyr008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
12 Ghiringhelli F, Vincent J, Guiu B, Chauffert B, Ladoire S. Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. Invest New Drugs. 2012;30:758-764. [PMID: 21057973 DOI: 10.1007/s10637-010-9575-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
13 Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F; Italian Society of Locoregional Therapies in Oncology (SITILO). Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103:324-331. [PMID: 20628388 DOI: 10.1038/sj.bjc.6605770] [Cited by in Crossref: 156] [Cited by in F6Publishing: 132] [Article Influence: 14.2] [Reference Citation Analysis]
14 Tantoy IY, Dhruva A, Cataldo J, Venook A, Cooper BA, Paul SM, Levine JD, Conley YP, Cartwright F, Lee K, Wright F, Miaskowski C. Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy. J Gastrointest Oncol 2017;8:109-26. [PMID: 28280616 DOI: 10.21037/jgo.2017.01.09] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
15 Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009;6:207-218. [PMID: 19333227 DOI: 10.1038/nrclinonc.2009.16] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
16 Molvar C, Lewandowski RJ. Intra-Arterial Therapies for Liver Masses. Radiologic Clinics of North America 2015;53:973-84. [DOI: 10.1016/j.rcl.2015.05.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther 2012;5:199-211. [PMID: 23055745 DOI: 10.2147/OTT.S30581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Medina-Echeverz J, Berraondo P. How can chemoimmunotherapy best be used for the treatment of colon cancer? Immunotherapy 2012;4:1787-90. [PMID: 23240744 DOI: 10.2217/imt.12.124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F, Cascinu S, Rosati G, Bilancia D, Nasti G, Iaffaioli RV, Lonardi S, Zagonel V, Zaniboni A, Marchetti P, Romiti A, Leone F, Aglietta M, Giordano M, Corsi DC, Ferraú F, Labianca R, Mosconi S, Ronzoni M, Gianni L, Rulli E, Poli D, Galli F, Torri V, De Simone I, Galli F, Pasini F, Rangoni G, Venezia R, Sozzi P, Nuzzo A, Berardi R, Frontini L, Rota S, Cozzi L. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. European Journal of Cancer 2017;83:106-15. [DOI: 10.1016/j.ejca.2017.06.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
20 Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. Journal of Controlled Release 2015;199:72-83. [DOI: 10.1016/j.jconrel.2014.11.031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
21 Zarva A, Mohnike K, Damm R, Ruf J, Seidensticker R, Ulrich G, Seidensticker M, Pech M, Ricke J, Amthauer H. Safety of repeated radioembolizations in patients with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy. J Nucl Med. 2014;55:360-366. [PMID: 24516256 DOI: 10.2967/jnumed.113.127662] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
22 Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol 2012; 18(10): 1104-1109 [PMID: 22416186 DOI: 10.3748/wjg.v18.i10.1104] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
23 Saxena A, Meteling B, Kapoor J, Golani S, Morris DL, Bester L. Is Yttrium-90 Radioembolization a Viable Treatment Option for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases? A Large Single-Center Experience of 302 Patients. Ann Surg Oncol 2015;22:794-802. [DOI: 10.1245/s10434-014-4164-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
24 Fernandes GDS, Braghiroli MI, Artioli M, Paterlini ACCR, Teixeira MC, Gumz BP, Girardi DDM, Braghiroli OFM, Costa FP, Hoff PM. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. J Gastrointest Cancer 2018;49:470-5. [PMID: 28884286 DOI: 10.1007/s12029-017-0001-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
25 Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:75-89. [PMID: 22423266 DOI: 10.1177/1758834011431592] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
26 Bouganim N, Mamo A, Wasserman DW, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P. Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. Curr Oncol 2013;20:247-51. [PMID: 24155628 DOI: 10.3747/co.20.1370] [Reference Citation Analysis]
27 Jary M, Borg C, Bouché O, Kim S, André T, Bennouna J. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?]. Bull Cancer 2015;102:758-71. [PMID: 26232849 DOI: 10.1016/j.bulcan.2015.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
28 Yoshida T, Takahashi K, Shibuya K, Muto O, Yoshida Y, Taguchi D, Shimazu K, Fukuda K, Ono F, Nomura K, Shibata H. Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. World J Gastrointest Oncol 2021; 13(4): 295-304 [PMID: 33889280 DOI: 10.4251/wjgo.v13.i4.295] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Yamaguchi K, Taniguchi H, Komori A, Narita Y, Nitta S, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K, Mori K, Igarashi Y. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. BMC Cancer 2015;15:601. [PMID: 26311588 DOI: 10.1186/s12885-015-1606-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
30 Hass P, Mohnike K. Extending the Frontiers Beyond Thermal Ablation by Radiofrequency Ablation: SBRT, Brachytherapy, SIRT (Radioembolization). Viszeralmedizin 2014;30:245-52. [PMID: 26288597 DOI: 10.1159/000366088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Sur D, Balacescu L, Cainap SS, Visan S, Pop L, Burz C, Havasi A, Buiga R, Cainap C, Irimie A, Balacescu O. Predictive Efficacy of MiR-125b-5p, MiR-17-5p, and MiR-185-5p in Liver Metastasis and Chemotherapy Response Among Advanced Stage Colorectal Cancer Patients. Front Oncol 2021;11:651380. [PMID: 34084747 DOI: 10.3389/fonc.2021.651380] [Reference Citation Analysis]
32 Bang YH, Kim JE, Lee JS, Kim SY, Kim KP, Kim TW, Hong YS. Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Sci Rep 2021;11:7118. [PMID: 33782470 DOI: 10.1038/s41598-021-86482-x] [Reference Citation Analysis]